Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha Mediocre results from the Phase 3a trial for cagrilintide and semaglutide #CagriSema in obesity and type 2 diabetes. Average weight loss at week 68 was 13.7% in the CagriSema group and 3.4% PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News